Scientific Program 

The entire program will be presented at the New York Academy of Medicine, therefore the time schedule below is Eastern Standard Time (EST).


01.00 pm  Registration opens
01.00 pm – 04.00 pm  Poster Viewing
04.00 pm – 04.10 pm  Welcome address
04.10 pm – 04.35 pm  Setting the stage – Historic perspectives
Georg Stingl (Vienna, Austria)
04.35 pm – 05.00 pm  Setting the stage – The translational revolution in inflammatory skin diseases
James G. Krueger (New York, NY, USA)
05.00 pm – 05.30 pm  Keynote lecture: Autoinflammatory diseases
Dan Kastner (Bethesda, MD, USA)
05.30 pm – 06.30 pm  Oral presentations from selected abstracts

Treatment of sarcoidosis with cutaneous involvement with tofacitinib: results of an open-label clinical trial with mechanistic insight
William Damsky

Extensive Lymphocyte Clonal Expansion and Formation of Tertiary Lymphoid Structure in Hidradenitis Suppurativa
Catherine Lu

RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis
Robert Bissonnette

Vitiligo Patients Show Significant Changes in Skin and Blood Immune/Melanocytes Biomarkers with Oral JAK3/TEC Inhibitor Ritlecitinib
Emma Guttman-Yassky

Efficacy and Safety Results of a Randomized, Double-blind, Vehicle-controlled Phase 2 Study of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis
Matthew Zirwas

Stratifying Risk for Early Onset Atopic Dermatitis from Birth: An Artificial Intelligence Empowered Clinical Decision Support Tool
Michael Brandwein

06.30 pm – 09.00 pm  Reception & poster viewing



08.15 am – 8.45 am Developmental programs in inflammatory skin disease
Muzlifah Haniffa (Newcastle, UK)
08.45 am – 09.15 am  Resident memory T cells in human health and disease
Rachael Clark (Boston, MA, USA)
09.15 am – 09.45 am Regulatory T cells in Skin
Michael Rosenblum (San Francisco, CA, USA)
09.45 am – 10.30 am Oral presentations from selected abstracts

Single-cell analysis unravels lineage plasticity of innate lymphoid cells in atopic dermatitis
Natalia Alkon

Commensal microbiome regulates epidermal barrier function and repair of the skin by signaling through the aryl hydrocarbon receptor
Aayushi Uberoi

Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis from infancy to adulthood
Tali Czarnowicki

10.30 am – 11.00 am COFFEE BREAK
11.00 am – 12.30 pm Sponsored Lunch Symposium (Non-CME)
supported by Sanofi Genzyme and Regeneron
12.30 pm – 12.45 pm COFFEE BREAK
12.45 pm – 02.15 pm Sponsored Lunch Symposium (Non-CME)
supported by UCB – Union Chimique Belge
02.15 pm – 02.30 pm COFFEE BREAK
The 2.30pm-4.00pm segment is non-CME, as Dr. Yancopoulos is an employee of Regeneron Pharmaceuticals.
02.30 pm – 03.00 pm Novel developments in ichthyoses
Amy S. Paller (Chicago, IL, USA)
03.00 pm – 03.30 pm Janus kinases in inflammation
John O’Shea (Bethesda, MD, USA)
03.30 pm – 04.00 pm New therapeutic frontiers in atopic conditions 
George Yancopoulos (Tarrytown, NY, USA)
04.00 pm – 04.30 pm COFFEE BREAK
04.30 pm – 05.00 pm Oral presentations from selected abstracts

Deucravacitinib, a Selective TYK2 Inhibitor: Serum Markers of Psoriatic Disease Activity and Pharmacodynamic Responses From a Phase 2 Study
Ian Catlett

Long-Term Efficacy of Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension Trial up to 172 Weeks
Lisa Beck

IL-13 and IL-4 Promote Proliferation and mRNA Expression of MUC2 and MUC5AC in Primary Human Conjunctival Goblet Cells
Maxim A.X. Tollenaere

05.00 pm – 05.30 pm Visualization of skin inflammation and resulting immunologic concepts
Kenji Kabashima (Kyoto, Japan)
05.30 pm – 06.00 pm Oral presentations from selected abstracts

Spatial transcriptomics of Cutaneous and Systemic Lupus Erythematosus skin reveals insights into cell-cell communications, interferon skewing, and distinguishes clinical subtypes
Nazgol Sadat Haddadi

IL-23 maintains tissue resident memory Th17 cells in murine and psoriatic skin
Sarah Whitley

Treatment with KHK4083 (AMG 451), an antagonist of OX40, induces durable modulation of atopic dermatitis (AD) related blood/skin biomarkers
Emma Guttman-Yassky

06.00 pm – 07.30 pm Sponsored Dinner Symposium (Non-CME)
supported by Boehringer Ingelheim Pharma GmbH & Co. KG
07.30 pm – 10.00 pm Scientific Networking session




08.00 am – 09.30 am Sponsored Breakfast Symposium (Non-CME)
supported by Incyte Corporation
09.30 am – 09.45 am  COFFEE BREAK
09.45 am – 10.15 am How to perform successful clinical trials in inflammatory skin diseases
Kristian Reich (Hamburg, Germany)
10.15 am – 10.45 am PSORT – New psoriasis frontiers
Christopher Griffiths (Manchester, UK)
10.45 am – 11.15 am Hidradenitis and pustular psoriasis
James G. Krueger (New York, NY USA)
11.15 am – 11.45 am Psoriasis – the translational path and access to drugs
Mark Lebwohl (New York, NY, USA)
11.45 am – 12.00 pm COFFEE BREAK
12.00 pm – 01.30 pm Sponsored Lunch Symposium (Non-CME)
supported by Janssen Immunology, Pharmaceutical Companies of
Johnson & Johnson
01.30 pm – 01.45 pm COFFEE BREAK
01.45 pm – 02.15 pm Atopic dermatitis
Emma Guttman (New York, NY, USA)
02.15 pm – 02.45 pm Dermatomyositis
Victoria P. Werth (Philadelphia, PA, USA)
02.45 pm – 03.15 pm Regulation of human T-Cell responses by ionic signals in the skin
Christina Zielinski (Munich, Germany)
03.15 pm – 03.45 pm Oral presentations from selected abstracts

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies
David Rosmarin

Sphingosine 1-phosphate receptor signalling promotes hair growth and inhibits perifollicular T-cell expansion and immune privilege collapse ex vivo
Marta Bertolini

Netherton syndrome subtypes share IL-17/IL-36 signature with distinct type I IFN, Th2 and Th9 responses
Alain Hovnanian

03.45 pm – 04.15 pm COFFEE BREAK
04.15 pm – 04.45 pm Translating Itch Neuroimmunology to New Therapies
Brian Kim (St Louis, MO, USA)
04.45 pm – 05.15 pm Immune and neural network interactions
Dan Kaplan (Pittsburgh, PA, USA)
05.15 pm – 05.45 pm The skin microbiome in wound healing and regeneration
Elizabeth Grice (Philadelphia, PA, USA)
05.45 pm – 06.15 pm Microbiome and immune interactions early in life
Tiffany Scharschmidt (San Francisco, CA, USA)
06.15 pm – 06.45 pm White adipose tissue and its role in innate host defense
Richard Gallo (San Diego, CA, USA)
06.45 pm – 07.00 pm COFFEE BREAK
07.00 pm – 08.30 pm Sponsored Dinner Symposium (Non-CME)
supported by Sanofi Genzyme and Regeneron



08.00 am – 09.30 am Sponsored Breakfast Symposium (Non-CME)
supported by Eli Lilly and Company
09.30 am – 09:45 am COFFEE BREAK
09.45 am – 10.15 am Artificial Intelligence in dermatology
Harald Kittler (Vienna, Austria)
10.15 am – 10.45 am Alopecia areata
Angela Christiano (New York, NY, USA)
10.45 am – 11.15 am Acne: a disorder of lipid metabolism
Robert Modlin (Los Angeles, CA, USA)
11.15 am – 11.45 am Vitiligo
John Harris (Worcester, MA, USA)
11.45 pm – 12.15 pm Inflammation and cancer
Thomas S. Kupper (Boston, MA, USA)
12.15 pm – 12.30 pm COFFEE BREAK
12.30 pm – 02.00 pm Sponsored Lunch Symposium (Non-CME)
supported by LEO Pharma
02.00 pm – 03.00 pm Oral presentations from selected abstracts

EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with tralokinumab
Jill Olydam

Histopathological Analysis of ECZTRA 1 Study Revealed the Reduction of Innate Lymphoid Cells in Skin of Atopic Dermatitis Patients After Tralokinumab Treatment
Toshiaki Kogame

Long-term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis
Emma Guttman-Yassky

Correcting immunological misfiring in obesity restores efficacy of targeted biologic therapy for inflammatory skin disease
Sagar Bapat

03.00 pm – 03.30 pm Lupus
Virginia Pascual (New York, NY, USA)
03.30 pm – 04.00 pm Sarcoidosis & Granulomatous diseases
Misha Rosenbach (Philadelphia, PA, USA)
04.00 pm – 04.30 pm Oral presentations from selected abstracts

Modulation of serum biomarkers from PsO patients treated with risankizumab or ustekinumab in a Phase 3 study
James Krueger

Sensory ganglia reprogram in response to cutaneous inflammation
Aaron Ver Heul

04.30 pm – 06.00 pm Sponsored Dinner Symposium (Non-CME)
supported by LEO Pharma
06.00 pm Closing & Farewell